Form 4: Inotiv Inc. Executive Acquires Stock Options

Jeffrey Brennan Freeman, VP-Finance & Corp. Controller of Inotiv, Inc., acquired 3,750 employee stock options on February 21, 2025.

Summary

• Jeffrey Brennan Freeman, VP-Finance & Corp. Controller of Inotiv, Inc., filed a Form 4 on February 25, 2025, reporting a transaction.
• On February 21, 2025, Freeman acquired 3,750 employee stock options with an exercise price of $4.205.
• These options vest over three years: 40% on February 21, 2026, 30% on February 21, 2027, and 30% on February 21, 2028, contingent upon continued employment.
• Following the transaction, Freeman directly owns 3,750 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing related to executive compensation. The acquisition of stock options can be seen as a slightly positive sign, indicating confidence, but it's not a major event.

Positives

• The acquisition of stock options by a company executive can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedule of the options suggests a multi-year commitment from the executive.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates that a key executive is incentivized through stock options, which is a common practice in the industry.

Comparison to Industry Standards

• Stock option grants are a common form of executive compensation in publicly traded companies, particularly in the biotech and pharmaceutical sectors where Inotiv operates.
• The vesting schedule of three years is fairly standard, aligning with typical retention strategies.
• Comparing the exercise price and the number of options granted to similar companies would require further analysis of executive compensation packages within Inotiv's peer group.

Key Dates